NOT FDA-APPROVED

KLOW Blend

A four-peptide blend: KPV + GLOW (GHK-Cu + BPC-157 + TB-500). Adds an anti-inflammatory mechanism to the GLOW skin formula. The "K" in KLOW stands for KPV, and the rest is exactly what it sounds like.

The 30-second read

The KLOW blend is the GLOW formula plus KPV, a tiny anti-inflammatory peptide derived from alpha-MSH. The pitch: the GLOW components handle skin synthesis, blood vessels, and cell migration; KPV adds NF-κB pathway inhibition to dial down the inflammation that often accompanies skin issues, gut concerns, or autoimmune-type conditions. Like GLOW, there are zero published human studies of the four-peptide KLOW combination. Each component has its own evidence base, strongest for topical GHK-Cu, thinnest for KPV (which has no human trials at all). Not FDA-approved. Three of the four components (BPC-157, TB-500, KPV) operate outside FDA-approved channels; the BPC-157 and TB-500 components are on the Category 2 list.

Why this blend is on people's radar

KLOW emerged when research-peptide community formulators noticed that the GLOW blend, while plausible for skin synthesis and tissue repair, didn't directly address inflammation. For people whose skin issues involve obvious inflammatory components, eczema, rosacea, psoriasis-type flares, post-procedure inflammation, or general inflamed-skin contexts, adding an anti-inflammatory peptide made theoretical sense. KPV, with its small size and selective NF-κB inhibition mechanism, was the natural choice.

The blend has caught on in two main contexts. First, complex skin conditions where inflammation is part of the picture, chronic eczema flares, persistent rosacea, conditions where standard cosmetic peptides may not address the underlying inflammation. Second, post-procedure recovery scenarios where reducing inflammation and supporting tissue repair are both desired (laser treatments, microneedling, scar revision).

The honest framing: KLOW takes the GLOW blend's already-thin clinical evidence and adds a fourth component (KPV) that has even less human evidence behind it. Adding more peptides may produce broader theoretical mechanism coverage; it doesn't necessarily mean better real-world outcomes. The longer the ingredient list, the more inferential leaps you're stacking.

What people are usually trying to do with it

People exploring the KLOW blend are usually focused on:

  • Calming inflammatory skin conditions (eczema, rosacea, psoriasis-type flares)
  • Combining anti-aging skin support with anti-inflammatory effects
  • Recovering from a cosmetic procedure with reduced inflammation
  • Supporting gut healing alongside skin healing (the gut-skin axis hypothesis)
  • Adding an inflammation-focused option to a broader peptide protocol

What the science actually shows

Plain-English summary, with the most important caveat first:

No human trials of the blend

Zero published human clinical trials of the KPV + GHK-Cu + BPC-157 + TB-500 combination. Anything anyone says about KLOW's effectiveness is extrapolated from individual-component research and from anecdote.

GHK-Cu individual research (the strongest part)

50+ years of cosmetic-science research, multiple human studies on topical use, consistent reports of collagen synthesis and skin firmness improvements. Full GHK-Cu explainer →

BPC-157 and TB-500 individual research

Both have decades of preclinical research with very limited human evidence. Together they form the Wolverine recovery stack. BPC-157 · TB-500

KPV individual research (the thinnest part)

Animal-model evidence for anti-inflammatory effects via NF-κB inhibition in gut and skin models. No published human clinical trials. Full KPV explainer →

Mechanistic complementarity (theoretical)

The four-peptide rationale: GHK-Cu drives matrix synthesis; BPC-157 supports angiogenesis; TB-500 facilitates cell migration; KPV reduces inflammation. Four different parts of the skin/tissue response. Plausible biology. Not proven synergy in humans.

What the blend has not been shown to do

Reliably improve any specific skin or inflammatory condition in a controlled human trial. Outperform topical GHK-Cu alone, conventional anti-inflammatory creams, or established dermatological treatments. Substitute for proper dermatological evaluation of inflammatory skin conditions.

The honest read

What's solid:

Each component has its own evidence base, with GHK-Cu's cosmetic-science research being the most credible piece. The four-mechanism complementarity argument is biologically reasonable. Individual-component reported tolerability has been generally favorable.

What's still unproven:

Effectively everything specific to the four-peptide combination in humans. There are no human trials of KLOW. KPV has no human trials at all individually. The leap from "four mechanisms in animal models" to "real benefit in human skin or gut conditions" is a long inferential chain.

What's hyped beyond the evidence:

Treating KLOW as an established treatment for any specific skin condition. The "stacking more peptides means better results" assumption, there's no clinical comparison showing four-peptide blends outperform one-peptide approaches. Marketing claims that KLOW works for autoimmune skin or gut conditions where established medical treatments exist with much more rigorous evidence.

Things to know if you're looking into it

  • How it's typically used: as a pre-mixed subcutaneous injection containing all four peptides. Some research-community protocols use components separately at their individual frequencies and routes (topical GHK-Cu + injectable others).
  • Component status: GHK-Cu is a widely available cosmetic ingredient. BPC-157 and TB-500 are on the FDA's Category 2 list (since September 2023). KPV is not currently on the Category 2 list and has less commercial-product structure around it.
  • Inflammation isn't always the right target: persistent skin or gut inflammation often has identifiable causes (food triggers, contact allergens, autoimmune disease, infection) that need diagnosis before any treatment. KLOW doesn't replace that workup.
  • Athlete bans: BPC-157 and TB-500 are on the WADA banned list. Competitive athletes will test positive even from the blend.
  • For inflammatory skin conditions: dermatologists have FDA-approved options (topical steroids, calcineurin inhibitors, biologics for severe cases) with clinical evidence. Those options should be considered before or alongside KLOW.
  • Healthcare provider involvement: recommended, especially for chronic inflammatory conditions where proper diagnosis matters.
  • Specific dosing protocols and component breakdowns: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

4-peptide blend (GHK-Cu : BPC-157 : TB-500 : KPV in a 5:1:1:1 ratio). Zero published human studies on this specific 4-peptide combination. None of the four is FDA-approved as a drug; BPC-157 and TB-500 are on the FDA Category 2 list. The dose math below uses combined peptide mass — because the components are unequal, a 1600 mcg combined dose is roughly 1000 mcg GHK + 200 mcg BPC + 200 mcg TB + 200 mcg KPV (the calculator shows the live breakdown). Compounded blend quality varies meaningfully — more components, more variation. WADA bans BPC-157 and TB-500. This is an educational reference, not dosing guidance.
Suggested start
1000 mcg/inj
~625 GHK + 125 BPC + 125 TB + 125 KPV
Common range
1600–2400 mcg/inj
Lands all four components in their per-component ranges
Max dose
3200 mcg/inj
~2000 GHK + 400 BPC + 400 TB + 400 KPV — community ceiling
Cycle
6–8 wks on
Then 2–4 weeks off — copper accumulation matters
mL
Defaults to ~27 mg/mL combined (3 mL into an 80 mg vial) — standard reconstitution that fits comfortably in the vial. Common dose draws land in the 4–12 syringe-unit range. For larger draw volumes, reconstitute with 5–6 mL water (13–16 mg/mL) and the units roughly double.
mcg
Subcutaneous injection, typically once daily. Blend ratio is 5:1:1:1 — for every 8 mcg combined, 5 mcg is GHK-Cu and 1 mcg each is BPC, TB, and KPV. So a 1600 mcg combined dose = 1000 mcg GHK + 200 mcg BPC + 200 mcg TB + 200 mcg KPV. The unequal ratio means "combined dose" isn't a free-standing number — what matters is whether each component lands in its individual range.
Concentration
26.7 mg/mL
Per dose
0.060 mL
6.0 units on insulin syringe
Doses per vial
~50
~50 days (~7.1 weeks) of daily dosing

When to stay put vs. adjust

Stay put at 1600 mcg combined daily when the inflammatory component you're targeting is gradually settling — redness reducing, irritation calming, post-procedure recovery progressing. KLOW's specific value over GLOW comes from the KPV anti-inflammatory addition, so the early signal to watch for is whether the inflammation actually changes, not just the skin-firmness or repair effects you'd track on GLOW alone.

Consider stepping to 2000–2400 mcg combined only after at least four weeks at 1600 mcg with clear tolerability and limited progress. Above 2400 mcg, you're putting the GHK-Cu component into its higher dose range; above 3200 mcg, you exit common protocols entirely.

Cycle off at the 6–8 week mark regardless of progress — the GHK-Cu copper component drives this requirement. Copper is a metal that can accumulate in tissues, and the off-period gives the body a clearance window. Same conservative practice applies to any blend containing GHK-Cu.

The frequency-mismatch problem is even more pronounced here than in GLOW. BPC-157 is normally daily; TB-500 is normally 1–2× weekly; GHK-Cu is normally 2–3× weekly; KPV is typically daily for gut/inflammatory uses. A pre-mixed daily-dosing KLOW blend forces all four onto the same schedule. The trade-off: one injection is more practical than four separate injections, but no clinical data shows the daily-blend schedule produces equivalent results to component-appropriate cadences. If you want individual-component dosing, use the four peptides as separate injections rather than a blend.

If inflammation is the primary target, ask whether you need the full blend. KPV alone has more focused anti-inflammatory data than the blend does. People reaching for KLOW specifically for inflammation control may get cleaner results from solo KPV (potentially with BPC-157 added for gut applications) than from the four-peptide combination. KLOW's strength is breadth, not depth; that's a feature for some use cases and a bug for others.

Watch for injection-site reactions and skin changes around the injection site. Copper-containing peptides can cause local irritation; rotate injection sites and reduce frequency or dose if redness, itching, or unusual skin changes appear. People with Wilson's disease or other copper-metabolism disorders should avoid copper peptides entirely — that includes any blend containing GHK-Cu.

Inflammation often needs diagnosis, not just treatment. Persistent inflammatory skin or gut conditions often have identifiable causes (food triggers, contact allergens, autoimmune disease, infection) that need workup before any treatment. KLOW doesn't replace that. For chronic inflammatory skin conditions, dermatologists have FDA-approved options with real clinical evidence; those should be considered before or alongside any peptide protocol.

The honest read. Zero published human trials of this specific 4-peptide combination — even thinner evidence than GLOW. KPV individually has preclinical IBD model data and very limited human evidence. The "stronger version of GLOW" framing is aspirational rather than evidence-based. The longer the ingredient list, the more inferential leaps you're stacking. Compounded blend quality varies meaningfully — more components means more room for variation between batches and suppliers.

For educational and research purposes only. This is not medical advice. None of the four components is FDA-approved as a drug; BPC-157 and TB-500 are on the FDA Category 2 list (Sept 2023). BPC-157 and TB-500 are on WADA and most pro/collegiate sports prohibited-substance lists. People with Wilson's disease or other copper-metabolism disorders should avoid this blend (it contains GHK-Cu). Compounded blends operate outside FDA drug oversight. Consult a licensed healthcare provider before any health decision.

What people often ask

Is KLOW better than GLOW?

No head-to-head trials. The case for KLOW over GLOW is that the added KPV component addresses inflammation specifically. Whether that translates into better outcomes versus GLOW alone, or versus proper topical anti-inflammatories used with GHK-Cu, isn't established.

Will it work for eczema or psoriasis?

The mechanistic case is plausible. There's no human evidence specific to KLOW for those conditions, and there are FDA-approved treatments with rigorous evidence. People with diagnosed inflammatory skin conditions should work with a dermatologist rather than relying on a research-peptide blend as primary treatment.

Can I use it for gut inflammation?

Theoretically the BPC-157 + KPV components target gut healing and inflammation. There are no human trials of KLOW for gut conditions. Persistent gut symptoms warrant proper evaluation (IBD has FDA-approved treatments with strong evidence).

Is it safe?

Each component has limited human safety data individually, and there's no safety data on the four-peptide combination specifically. Reported side effects in research-community use are generally mild and uncommon.

Is more peptides better?

Honest answer: not necessarily. Stacking mechanisms theoretically covers more biology. It also stacks inferential leaps and complicates safety analysis. The longer the ingredient list, the harder it is to know what's doing what.

What's the difference from KLOW vs GLOW?

KLOW = GLOW + KPV. The "K" prefix is for KPV. So KLOW is the GLOW formula (GHK-Cu + BPC-157 + TB-500) plus the anti-inflammatory KPV component on top.

Is it FDA-approved?

No. Not approved as a combined formulation. Two of the four components (BPC-157, TB-500) are on the FDA's Category 2 list as of September 2023.

FDA and regulatory status

Status as of May 5, 2026: The KLOW blend is not FDA-approved as a combined formulation. GHK-Cu is widely available as a cosmetic ingredient (not on the Category 2 list). BPC-157 and TB-500 are both on the FDA's Category 2 list (since September 2023). KPV is not currently on the Category 2 list and operates outside FDA drug oversight. The April 2026 FDA panel review of compounded peptides included BPC-157 and TB-500 but not KPV. Status updates land here when they happen.

Want to go deeper? Component breakdowns, mechanism complementarity, blend dosing considerations, side effects, and references. Click to expand.

The four components, briefly

KPV, the anti-inflammatory addition (the K)

A three-amino-acid peptide derived from alpha-MSH. Animal-model evidence for NF-κB pathway inhibition and anti-inflammatory effects in gut and skin models. No human trials. Read the full KPV explainer →

GHK-Cu, the copper-peptide skin specialist

A copper-binding tripeptide with 50+ years of cosmetic-science research. Strongest evidence for topical use. Read the full GHK-Cu explainer →

BPC-157, angiogenesis and growth-factor signaling

A 15-amino-acid peptide derived from human gastric juice. Animal-model evidence for tissue-repair effects. Read the full BPC-157 explainer →

TB-500, cell migration

A 17-amino-acid synthetic fragment of Thymosin Beta-4. Animal-model evidence for cell migration during tissue repair. Read the full TB-500 explainer →

Mechanism of the combination (theoretical)

The four-component logic:

  • KPV: NF-κB pathway inhibition reduces pro-inflammatory cytokines (IL-6, TNF-α, IL-8) without broadly suppressing immunity.
  • GHK-Cu: upregulates collagen and elastin synthesis, antioxidant effects via copper cofactor.
  • BPC-157: promotes new blood-vessel formation and growth-factor expression.
  • TB-500: supports cell migration and tissue reorganization.
  • Combined story: KPV calms the inflammatory response that often accompanies skin or tissue stress; GHK-Cu drives matrix synthesis; BPC-157 brings the supply lines; TB-500 helps cells migrate to where they're needed. Four layers of skin/tissue response.

Plausible biology, untested combination.

Commonly studied dosing of components

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Pre-mixed blend products: typical formulations contain KPV (typically 5–10 mg), GHK-Cu (typically 50–100 mg), BPC-157 (5–10 mg), and TB-500 (5–10 mg) per multi-dose vial. Daily-dosing protocols are most common.

Component-by-component research-community protocols: some users prefer topical GHK-Cu (cosmetic concentrations daily) plus injectable KPV + BPC-157 + TB-500, or further separating BPC-157 (daily) from TB-500 (1–2x weekly) per the components' individual pharmacology.

Treatment duration: typical research-community cycle ranges are 4 to 8 weeks. Long-term continuous use of the four-peptide blend has not been characterized.

Side effects and safety considerations

Reported in research-community use of the components individually or as a blend:

  • Mild injection-site reactions
  • Mild flushing or warmth shortly after dose
  • Mild GI symptoms (uncommon)
  • Mild headache (uncommon)

Theoretical considerations: people with Wilson's disease or copper-metabolism disorders should avoid copper-containing peptides. People with active malignancy should be cautious about angiogenesis-promoting peptides. Long-term safety in healthy adults using continuous four-peptide blends is not characterized, and the more components, the harder it becomes to attribute any observed effect to a specific peptide.

References

  1. PubMed search of "KPV + GHK-Cu + BPC-157 + TB-500" or related four-peptide combinations: no published human clinical trials identified as of May 2026. PubMed
  2. Kannengiesser K, Maaser C, Heidemann J, et al. (2008). "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis, 14(3), 324–331. PubMed
  3. Pickart L. (2008). "The human tripeptide GHK and tissue remodeling." J Biomater Sci Polym Ed, 19(8), 969–988. PubMed
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. (2012). "Thymosin β4: a multi-functional regenerative peptide." Expert Opin Biol Ther, 12(1), 37–51. PubMed
  5. Sikiric P, Seiwerth S, Grabarevic Z, et al. (2018). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal healing." Curr Pharm Des, 24(18), 1990–2001. PubMed
For educational and research purposes only. This is not medical advice. The KLOW blend is not FDA-approved as a combined formulation. There are no published human clinical trials of this combination. Two of the four components (BPC-157, TB-500) are on the FDA's Category 2 list. Inflammatory skin or gut conditions should be evaluated and treated by qualified clinicians using FDA-approved options. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.